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INTRODUCTION
Idiopathic pulmonary fibrosis (IPF) is a progres-
sive, lethal disease of the lungs that is characterized
by distorted lung architecture and loss of respiratory
function as a result of proliferation of fibroblasts
and increased deposition of the extracellular matrix
(1, 2). Although corticosteroids and other immuno-
suppressants have been used to treat IPF, the 5-
year survival rate of patients with the disease is less
than 50% (3, 4). For this reason, novel therapeutic
modalities are of great interest.
CCN6/Wnt1-inducible signaling protein-3 (CCN6/
WISP-3) is a cysteine-rich protein that belongs to
the CCN family, which consists of six members,
CCN1 (CYR61/cysteine-rich 61), CCN2 (CTGF/
connective tissue growth factor), CCN3 (NOV/neph-
roblastoma overexpressed gene), CCN4 (WISP1/
Wnt1-inducible signaling protein-1), CCN5 (WISP2/
Wnt1 - inducible signaling protein - 2), and CCN6
(5 - 10). Apart from CCN5, all CCN proteins are
composed of 4 conserved cysteine-rich modular
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domains ; an insulin-like growth factor binding pro-
tein - like module (IGFBP) ; a von Willebrand factor
type C repeat module (VWC) ; a thrombospondin
type 1 (TSP1) domain ; and a cysteine-knot-contain-
ing module (CT), which contains several cysteine-
knot motifs (6).
CCN proteins act by binding to specific integrin
receptors, heparin sulfate proteoglycans, thereby
triggering a wide range of biological functions, such
as cell adhesion, proliferation, migration, differentia-
tion, and survival. They can also modulate the activi-
ties of other growth factors and cytokines (6, 8, 10).
CCN proteins have been shown to be associated
with IPF. In particular, CCN2 frequently acts down-
stream of the TGF-β -mediated fibrogenic pathway
(11). The CCN2 produced by type II alveolar cells
has the potential to stimulate fibroblast prolifera-
tion and the production of the extracellular matrix
involved in pulmonary fibrosis (12). It has been
shown that CCN2 expression is upregulated in bleo-
mycin-induced lung fibrosis (13). In addition, tran-
sient overexpression of CCN2 in fibrosis-resistant
mice creates a profibrotic microenvironment in the
lung, leading to the development of progressive fi-
brosis in response to bleomycin (14). Moreover,
CCN2 neutralizing antibodies have been shown to
be at blocking pro-fibrogenic CCN2 signaling path-
ways in vitro and have yielded promising data with
respect to the prevention or reversal of fibrosis in
several animal models in vivo (11).
A recent study has shown that CCN4 enhances
fibrogenesis by inducing EMT in ATII cells and in-
creasing collagen production by fibroblasts. In ad-
dition, CCN4 neutralization resulted in marked at-
tenuation of bleomycin-induced lung fibrosis (15).
CCN6 has been proposed to take part in cell sur-
vival and has been shown to modulate IGF-I-medi-
ated growth and the proliferation of breast epithe-
lial cells (16). In addition, frequent mutations in the
CCN6 gene were reported to be associated with
autosomal recessive skeletal disorder progressive
pseudorheumatoid dysplasia (17). However, no stud-
ies have been carried out to investigate the involve-
ment of CCN6 in the proliferation of lung fibroblasts
or the pathogenesis of pulmonary fibrosis.
In the present study, we demonstrate that CCN6
stimulates the proliferation of lung fibroblasts by
binding to integrin β1, leading to the autophospho-
rylation of FAK. CCN6 protein expression was
highly upregulated in a bleomycin-treated pulmo-
nary fibrosis model.
MATERIALS AND METHODS
Fibroblast Isolation
The primary culture of murine lung fibroblasts
was obtained according to the method reported by
Phan et al. (18). The lungs were harvested from
untreated 8-week-old C57BL/6 mice. The minced
lungs were digested with 0.5% trypsin under stir-
ring, and the cells were collected by centrifugation.
The harvested cells were cultured in RPMI 1640
(Nissui Pharmaceutical Co. Tokyo, Japan) supple-
mented with 10% fetal bovine serum (FBS) (GIBCO,
Grand Island, NY), penicillin (100 U/ml), and strep-
tomycin (50 mg/ml) at 37in a humidified atmos-
phere of 5% CO2 in air for several days. The prolif-
erating cells (doubling time in 10% FBS : 15 to 18
hours) were used as lung fibroblasts at the fifth to
tenth passage. These cells were termed C57BL/6
lung fibroblasts (19). MLg lung fibroblasts were ob-
tained from ATCC (Manassas, VA).
Reagents and Antibodies
Recombinant human CCN6/WISP-3 was pur-
chased from Peprotech (Rocky Hill, NJ). PDGF-
BB was purchased from Sigma-Aldrich (St Louis,
MO). Recombinant TGF-β1 was purchased from
Santa Cruz (Santa Cruz, CA). The blocking mono-
clonal Abs against mouse CD29 (integrin β1) and
CD51 (integrin αV) and antibodies for flow cytome-
try against mouse CD29 (integrin β1), CD18 (in-
tegrin β2), CD61 (integrin β3), CD104 (integrin
β4), integrin β7, CD49f (integrin α6), CD51 (in-
tegrin αV), VLA -5 (CD49e/CD29) (α5β1) were
purchased from BD Biosciences, Pharmingen (San
Jose, CA). Rabbit anti-phosphoFAK(pY397) was pur-
chased from Invitrogen (Carlsbad, CA). Mouse anti-
FAK antibody was purchased from BD Biosciences.
The antibody for CCN6 was purchased from Santa
Cruz.
Mice and Bleomycin Treatment
Eight-week-old female C57BL/6 mice were pur-
chased from Charles River Japan, Inc. (Yokohama,
Japan) and were maintained in the animal facility
of the University of Tokushima under specific patho-
gen-free conditions according to the guidelines of
our university. Bleomycin (BLM) was purchased
from Nippon Kayaku Co. (Tokyo, Japan). Osmotic
minipumps (model 2001 ; Alza Pharmaceuticals, Palo
Alto, CA) containing 200 μl of saline with or without
BLM (125 mg/kg) were implanted subcutaneously
(20-22) [26-28]. Each experiment involved at least
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four mice per group.
Proliferation Assay
The C57BL/6 and MLg lung fibroblasts (8103
cells per well) were cultured in 96-well flat-bot-
tomed tissue plates in RPMI1640 supplemented with
10% FBS, and then serum-starved in medium con-
taining 0.1% FBS overnight (19, 20, 22) [19, 27, 28].
Next, the cells were treated with various doses (1
to 200 ng/ml) of CCN6, and PDGF-BB (10 ng/ml)
as a positive control for 72 hours, and labeled with
3H - thymidine deoxyribose (TdR) (6.7 Ci/mmol ;
Amersham Corp., Arlington Heights, IL) at 1 μCi/
well for the final 18 hours. In the blocking experi-
ment, the cells were incubated with CCN6 (200 ng/
ml) with or without monoclonal Ab against CD29
(40 μg/ml) or monoclonal Ab against CD51 (50 μg/
ml). The cells were harvested in a MASH II cell har-
vester (Labo Science Co. Tokyo, Japan), and the in-
corporation of 3H-TdR was determined by liquid
scintillation counting. The experiments were per-
formed in triplicate. In addition, proliferation was as-
sessed by cell counting 4 and 7 days after stimula-
tion with CCN6 (200 ng/ml), with counting per-
formed at least 3 times for each condition.
Flow Cytometry Assay
To assess the cell surface expression of integrins,
C57BL/6 and MLg lung fibroblasts (80%conflu-
ent) were trypsinized and washed in cold PBS, and
the cells were incubated with 1 μg of primary anti-
bodies for 30 min on ice, washed again with cold
PBS, incubated with FITC conjugated secondary an-
tibodies, and resuspended in cold PBS. Flow cy-
tometric analysis was carried out using a FACS
Calibur (BD Biosciences), and the results were ana-
lyzed with CELLQuest software (BD Biosciences)
(23, 24).
Western Blot Analysis
Serum-starved C57BL/6 lung fibroblasts were
treated with recombinant CCN6 (200 ng/ml) for
10, 30, or 60 minutes before being harvested (19).
Then, the cells were lysed in cell lysis buffer (Cell
Signaling Technology, Beverly, MA) containing 1
mM PMSF. To detect CCN6 expression in BLM-
treated lung tissue, lung tissues were homogenized
and lysed in RIPA Buffer (Pierce, Rockford, IL).
Their protein concentrations were determined us-
ing the Bradford protein assay (Sigma-Aldrich) (19,
20). Immunoprecipitation was performed using 500
μg of total proteins, and immune complexes were
recovered with Protein G-Sepharose beads (Zymed
Laboratories, South San Francisco, CA) (19, 20). For
Western blotting analysis, immunoprecipitates or
30 μg of total protein were resolved by SDS-PAGE
(Bio -Rad, Hercules, CA), and the proteins were
then transferred to PVDF membranes (Atto, Tokyo,
Japan). After being washed 3 times, membranes
were incubated with Blocking One (Nacalai Tesque
Inc, Japan) for 1 hour at room temperature and then
incubated with the primary antibodies against phos-
pho-FAK(pY397), FAK, β -actin, and CCN6 (1 : 1000
dilution) overnight at 4. Then, the membranes
were incubated for 2 hours at room temperature
with species-specific horseradish peroxidase conju-
gated secondary antibodies. Immunoreactive bands
were visualized using an enhanced chemilumines-
cent substrate (Pierce, Rockford, IL).
Quantitative Real Time-PCR analysis
C57BL/6 lung fibroblasts (1106 cells//well)
were seeded on to a 10 cm well plate in RPMI1640
with 10% FBS, before being serum-starved in me-
dium containing 0.1% FBS overnight. The cells were
treated with or without CCN6 or TGFβ (200 ng/ml
or 5 ng/ml) for 24, 48, or 96 hours. Quantitative real
time-PCR analysis was performed according to the
previously described method (25). The total RNA
of the cells was extracted using the RNAeasy kit ac-
cording to the manufacturer’s instructions (Qiagen,
Valencia, CA). Total RNA were reverse transcribed
using an Omniscript RT kit (Qiagen). The expres-
sion of fibronectin, type 1 collagen, and β -actin was
measured by quantitative RT-PCR analysis on an
ABI 7700 Sequence Detection system (Applied Bio-
systems, Foster City, CA). The quantitative RT-PCR
experiments were performed in triplicate, and the
relative expression levels were calculated based on
the comparative Ct method.
Statistical Analysis
One-way ANOVA with Dunnett‘s post-hoc test
was performed using GraphPad Prism version 5.01
for Windows, GraphPad Software (San Diego, CA).
P0.05 was considered statistically significant.
RESULTS
Effects of CCN6 Protein on the Proliferation and
Expression of Extracellular Matrices of Mouse Lung
Fibroblasts
To investigate whether CCN6 stimulates the
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proliferation of lung fibroblasts, C57BL/6 and MLg
lung fibroblasts were plated in 96 well plates and
treated with CCN6, and cell proliferation was meas-
ured with the 3H-TdR incorporation assay. As shown
in Figure 1A, the proliferation of C57BL/6 lung fi-
broblasts was induced by recombinant CCN6 at
more than 100 ng/ml. Next, we examined the pro-
liferation of MLg lung fibroblasts. CCN6 also stimu-
lated the growth of MLg fibroblasts at more than
100 ng/ml (Figure 1B). To confirm these results,
we counted the numbers of C57BL/6 and MLg
fibroblasts after treatment with CCN6. Treatment
with CCN6 (200 ng/ml) significantly increased the
number of C57BL/6 (Figure 1C) and MLg (Figure
1D) fibroblasts on days 4 and 7.
The accumulation of ECM proteins, including col-
lagens, fibronectin, proteoglycans, and elastin, has
long been considered a hallmark of fibrosis. The
ECM plays a vital early role in the repair process,
orchestrating the modulation and transition of cell
phenotype and function (26). It has been shown that
CCN6 stimulates collagen type II, aggrecan, and su-
peroxide dismutase expression and activity in chon-
drocytes (27, 28). To investigate whether CCN6 af-
fects on ECM production, we treated C57BL/6 cells
with CCN6 and examined the mRNA expression of
Figure 1 Effects of CCN6 protein on the proliferation and expression of the extracellular matrixes of mouse lung fibroblasts
C57BL/6 (A) and MLg (B) mouse lung fibroblasts (8103 cells/well) were cultured in 96-well flat -bottomed tissue culture plates in
RPMI1640 containing 10% FBS for 24 hours and then serum starved in medium containing 0.1% FBS overnight before treatment with
various doses of CCN6, or PDGF-BB (10 ng/ml) as a positive control. The cells were labeled with 3H-TdR at 1 μCi/well for the final
18 hours, and the incorporation of 3H-TdR was measured with a liquid scintillation counter. C57BL/6 (C) or MLg (D) fibroblasts
(4104 cells/well) were cultured in 6-well flat -bottomed tissue culture plates and then treated with CCN6 (200 ng/ml) for 7 days.
The number of cells was counted on Days 4 and 7. Data are presented as the meanSD of triplicate cultures.
C57BL/6 fibroblasts (1106 cells/well) were serum-starved for 24 hours before being incubated with CCN6 (200 ng/ml) or TGF-β1 (5
ng/ml) for the indicated time periods. Then, the total RNA of the cells was extracted, and the mRNA expression levels of type 1 collagen
and fibronectin were determined by quantitative real - time RT-PCR. The mRNA expression levels of fibronectin (E) and type 1 collagen
(F) presented have been normalized to β -actin using the Ct method. Similar results were obtained in three separate experiments. (*) p
0.05 vs untreated control (one-way ANOVA with Dunnett‘s post-hoc test). The data is representative of three independent experiments.
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fibronectin and type I collagen by real-time RT-PCR
analysis. Treatment with TGF-β1 significantly stimu-
lated the expression of both fibronectin (Figure 1E)
and type 1 collagen mRNA (Figure 1F). On the
other hand, CCN6 slightly but significantly stimu-
lated the expression of fibronectin mRNA (Figure
1E), but not type 1 collagen mRNA (Figure 1F).
Integrin Expression on the Surface of Mouse Lung
Fibroblasts
Integrins mediate cellular adhesion to extra-cel-
lular matrices (ECM), which are important for many
cellular processes including growth, transformation,
migration, survival, and differentiation (29). Most of
the activities of CCN proteins in isolated cell sys-
tems can be attributed to their direct interaction with
integrin receptors, which function as co-receptors
with HSPG in all cases in some contexts (10).
Therefore, we examined the expression of integrins
by C57BL/6 and MLg lung fibroblasts. As shown in
Figure 2, C57BL/6 and MLg fibroblasts expressed
integrins β1, αV, α6 and α5β1. However, the ex-
pression of integrins α1, α2, α3, α4, β2, β3, β4 and
β7 was not detected in both fibroblasts (data not
shown).
Blocking Monoclonal Antibodies against Integrins
Inhibit the Proliferative Effect of CCN6 on C57BL/6
Lung Fibroblasts
Since most activities of CCN proteins are known
to be mediated through integrins (6, 10, 30, 31),
we next examined which integrin is involved in the
signaling pathway mediated by CCN6 in lung fi-
broblasts. We performed blocking experiments to
block the growth of lung fibroblasts using two anti-
bodies against integrin β1 (CD29) and αV (CD51).
C57BL/6 lung fibroblast cells were treated with
CCN6 protein and antibodies against integrin β1
(CD29) or αV (CD51). As depicted in Figure 3A,
CCN6-induced proliferation of lung fibroblasts was
partially inhibited by anti-β1(CD29) antibody, but
not by anti-αV (CD51) antibody. These findings
suggest that CCN6 exerts a proliferative effect on
lung fibroblasts at least in part by binding to integrin
β1.
FAK Signaling Pathway is involved in the CCN6-
induced Proliferation of C57BL/6 Lung Fibroblasts
Focal adhesion kinase (FAK), a potential can-
didate-signaling molecule, has been shown to be
Figure 2 Flow cytometric analysis of integrin expression in lung fibroblasts
C57BL/6 (A) and MLg (B) lung fibroblasts (80% confluent) were trypsinized and washed twice in cold PBS. The cells were incu-
bated with 1 μg of primary antibody for 30 min on ice, before being washed again with cold PBS, pelleted, and resuspended in cold
PBS. Flow cytometric analysis was carried out using FACS Calibur and analyzed with CELLQuest software. The histograms show
the findings produced with the antibody for each integrin (filled area) and control IgG (transparent area).
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capable of regulating integrin-mediated survival sig-
naling (32). Integrin engagement with extracellular
matrix proteins activates the phosphorylation of the
Tyr397 of FAK, which plays a critical role in integrin-
mediated cell functions, such as cell proliferation
and migration (33, 34). Therefore, we investigated
whether CCN6 can stimulate the FAK signaling
pathway using Western blotting for pFAKY397 (Figure
3B). As previously reported (35), TGF-β1 stimu-
lated the phosphorylation of FAKY397 30 minutes after
its addition. In this experimental condition, CCN6
also induced the phosphorylation of FAKY397.
These findings suggest that CCN6 stimulates the
proliferation of lung fibroblasts by binding to integrin
β1 and leads to the autophosphorylation of FAKY397.
Increased Expression of CCN6 in the Lungs of
BLM-treated Mice
Finally, to investigate the expression of CCN6 in
lung fibrosis, we analyzed the expression of CCN6
in a BLM-treated pulmonary fibrosis model. The
expression of CCN6 in BLM-treated lungs was ex-
amined by Western blotting. As shown in Figure 4,
CCN6 exhibited increased expression on Day 3 after
BLM administration, and the high level of CCN6
expression continued until Day 14, before decreas-
ing on Day 28.
Figure 3 Integrin β1 and focal adhesion kinase are involved in the signaling pathway mediated by CCN6
A : The blocking antibodies against integrins inhibit the proliferation of C57BL/6 lung fibroblasts induced by CCN6. C57BL/6 lung
fibroblasts (8103 cells/well) were cultured in 96-well flat -bottomed tissue culture plates and treated with CCN6 (200 ng/ml) in the
presence or absence of anti -β1(CD29) antibody (40 μg/ml) and anti -αV (CD51) antibody (50 μg/ml). PDGF-BB (10 ng/ml) was
used as a positive control. The cells were labeled with 3H-TdR at 1 μCi/well for the final 18 hours, and the incorporation of 3H-TdR
was measured. Data are presented as the meanSD of triplicate cultures. (*) p0.05 CCN6 vs CCN6+anti -β1 (CD29). B : CCN6
induces the autophosphorylation of FAKY397. C57BL/6 fibroblasts (80% confluent) were serum-starved overnight, and incubated with
CCN6 (200 ng/ml) or TGF-β1 (5 ng/ml) for the indicated time periods before being harvested. The autophosphorylation of FAKY397
was determined by Western blot analysis. For semiquantitation, the intensities of the bands for FAK, pFAK, and β -actin were calcu-
lated using a densitometer. The bars show the relative pFAK/FAK ratio. Equal protein loading was confirmed by β -actin. Similar
results were obtained in three separate experiments.
Figure 4 The level of CCN6 in lung homogenate was elevated
in the lungs of bleomycin-treated mice
Eight-week-old C57BL/6 mice were implanted with osmotic
minipumps containing saline or bleomycin (125 mg/kg). On
the days indicated, the mice were killed, and lung tissues were
homogenized. The expression level of CCN6 was determined
by Western blotting assay using CCN6 antibody (1 : 1000 dilu-
tion range). For semiquantitation, the intensities of the CCN6
and β -actin bands were calculated using a densitometer. The bars
show the relative CCN6/β -actin ratio. Equal protein loading was
confirmed by β -actin.
The Journal of Medical Investigation Vol. 58 August 2011 193
DISCUSSION
Numerous studies have shown that CCN1, CCN2,
and CCN3 have no intrinsic ability to stimulate cell
proliferation on their own, but can enhance DNA
synthesis induced by other mitogenic growth factors
(6, 18, 30, 36, 37). A recent study by Königshoff et
al. has shown that CCN4 acts as a proliferative me-
diator of ATII cells, but has no effect on the prolif-
eration of lung fibroblasts. Moreover, they demon-
strated that CCN4 treatment resulted in a marked
increase in fibronection and type 1 collagen produc-
tion by fibroblasts (15). In the current study, we
showed that, CCN6 has the ability to induce the pro-
liferation of lung fibroblasts and the production of
fibronectin by fibroblasts. These results suggest that
CCN6 is involved in the proliferation of fibroblasts
and ECM production by lung fibroblasts.
CCN proteins utilize distinct integrins depending
on the target cell type and the activity being medi-
ated. In fibroblasts, CCN1 promotes growth factor-
induced cell proliferation, adhesion, and migration
through αVβ3, α6β1, and αVβ5, respectively. In
contrast, it stimulates cell migration in endothelial
cells and vascular smooth muscle cells by binding
to αVβ3 and α6β1, respectively (6, 38). It has been
reported that CCN6 stimulates the migration of un-
differentiated mesenchymal stroma cells through in-
tegrin αVβ5 (31). In the current study, we showed
that fibroblasts expressed integrins β1, αV, α6 and
α5β1 and that CCN6-induced proliferation of lung
fibroblasts was partially inhibited by anti-β1(CD29)
antibody, but not by anti-αV (CD51) antibody.
These findings suggest that α5β1 or α6β1 play a
critical role in the signaling pathway of CCN6 in lung
fibroblasts. In addition, we demonstrated the auto-
phosphorylation of FAKY397 in response to CCN6.
Although western blotting analysis showed the simi-
lar time course of the phosphorylation of FAKY397 by
CCN6 as compared to TGF-β stimulation (figure
3B), the further analysis is required to clarify the
signaling pathway involved in the phosphorylation
of FAKY397.
A recent study by Königshoff et al. (15) showed
that CCN6 mRNA was detectable in primary fibro-
blasts and ATII cells isolated from BLM-treated
mouse lungs, which supports our findings. However,
they reported that CCN6 was not elevated in the
lung homogenates of BLM-treated mice, which is
not consistent with the elevated CCN6 in the lungs
of BLM-treated mice in the current study. The rea-
son for the discrepancy between the two studies is
unclear. The differences in BLM-models used in the
two studies might have affected the expression of
CCN family proteins in the lungs. In addition, we
examined the expression of CCN6 by Western blot-
ting at the protein level, whereas they performed
RT-PCR and microarray analysis at the mRNA level.
Further analyses of the expression of CCN6 protein
might be required.
When considering the roles of CCN6 for lung
fibroblasts in vitro experiments, which has been
showed in the current study, it is reasonable to ex-
pect that the early elevation of CCN6 expression
in the lungs may be associated with the growth of
fibroblasts and ECM production by fibroblasts in
the fibrotic areas of the lungs and resulting in pro-
gression of lung fibrosis in BLM-treated mice. In
addition, Kleer and colleagues reported that CCN6
was essential to induce the process of epithelial-
mesencymal transition (EMT) with repression of E-
cadherin gene expression and induction of a protein
expression program characteristic of EMT in human
mammary epithelial cells (39). Considered together,
CCN6 may also play an important role in develop-
ment of lung fibrosis via inducing EMT, which is
one of critical cellular modulators of fibrosis, al-
though further studies including in vitro and in vivo
experiments are necessary to test whether CCN6
is involved in induction of EMT in the lungs, re-
sulting in progression of lung fibrosis.
CONCLUSIONS
CCN6, a member of the CCN family of secreted
cysteine-rich matricellular proteins, induces the pro-
liferation of lung fibroblasts by binding to integrin
β1 and leads to the autophosphorylation of FAKY397.
Moreover, CCN6 was highly expressed in the lungs
of BLM-treated mice and induced fibronectin pro-
duction in lung fibroblasts. Since these data strongly
suggest that CCN6 plays a role in the pathogenesis
of pulmonary fibrosis in mice, further studies in
humans are necessary to understand the molecular
mechanisms of CCN6 signaling in pulmonary fi-
brosis.
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